Triple-Drug Antibody-Drug Conjugate Strategy Shows Promise in Hard-to-Treat Breast Cancer

Metastatic triple-negative breast cancer remains one of the most formidable challenges in oncology. Lacking the estrogen receptor, progesterone receptor, and HER2 that anchor targeted therapies in other breast cancer subtypes, this aggressive disease leaves patients with few options once first-line treatment fails. Conventional chemotherapy in the later-line setting typically produces objective response rates of only 5 to 20 percent and median progression-free survival of just two to four months, all while inflicting myelosuppression and neurotoxicity on already weakened patients. Against this grim backdrop, a new real-world study from Sun Yat-sen Memorial Hospital in Guangzhou, China, offers a striking signal that a three-drug strategy built around Trop-2-directed antibody-drug conjugates may substantially extend the benefit of modern targeted therapy for these patients.

The study, published in Breast Cancer Research and Treatment, retrospectively analyzed 87 women with metastatic triple-negative breast cancer who received Trop-2 antibody-drug conjugates between April 2020 and December 2025. Nearly all patients were treated with sacituzumab govitecan, an antibody-drug conjugate that links a topoisomerase I inhibitor payload to an antibody targeting Trop-2, a cell-surface protein abundantly expressed in triple-negative tumors. Two patients received sacituzumab tirumotecan, a related agent. Patients were divided into three groups: 60 received the antibody-drug conjugate alone, 13 received it together with the PD-1 inhibitor pembrolizumab, and 14 received a triple-agent regimen combining the antibody-drug conjugate, pembrolizumab, and the oral anti-angiogenic drug apatinib. All patients received at least two cycles of therapy in the second-line or later setting.

The results describe a clear stepwise gradient of activity. The objective response rate was 31.7 percent with monotherapy, 38.5 percent with the dual combination, and 57.1 percent with the triple-agent regimen. Disease control rates followed the same pattern, rising from 78.3 percent to 84.6 percent and then to 92.9 percent. More consequential still were the survival figures. Median progression-free survival was 3.8 months with monotherapy, 10.0 months with the dual combination, and 15.4 months with the triple-agent combination, over a median follow-up of 15.2 months. In pooled analysis, any combination therapy was associated with a hazard ratio of 0.387 for progression or death compared with monotherapy, and the benefit persisted after propensity-score-based overlap weighting, with an adjusted hazard ratio of 0.49.

The biological logic underlying the triplet is rooted in the interplay between tumor vasculature and antitumor immunity. Low-dose VEGF pathway inhibition is known to promote vascular normalization within tumors, reversing the hypoxic, immunosuppressive microenvironment that blunts immune checkpoint blockade. Preclinical work has shown that anti-angiogenic therapy enhances CD8-positive T cell activity, and that the OPN-TGF-beta pathway upregulates PD-1 on these T cells, increasing their sensitivity to PD-1 blockade. Clinical evidence has been accumulating in parallel: the ATRACTIB trial suggested that adding bevacizumab to atezolizumab and paclitaxel improved outcomes including in PD-L1-negative disease, and a multicenter phase II trial of camrelizumab, apatinib, and eribulin achieved a 37 percent response rate in heavily pretreated patients regardless of PD-L1 status. The new study extends this concept to an antibody-drug conjugate backbone.

Importantly, the exploratory subgroup analyses suggested that the activity of the triple-agent combination may not be confined to PD-L1-positive tumors. The interaction P-value between treatment effect and PD-L1 status was 0.098, and among the 39 patients with confirmed PD-L1-positive disease, median progression-free survival had not been reached in the triplet group compared with 5.0 months on monotherapy, a statistically significant difference. Prior treatment with a PD-1 inhibitor, documented in roughly half of the cohort, also did not appear to diminish the benefit of the triplet, with an interaction P-value of 0.828. This is clinically meaningful because primary resistance to checkpoint inhibitors occurs in approximately 60 percent of PD-L1-negative triple-negative breast cancers, and immunotherapy rechallenge after progression is often viewed with skepticism.

One of the most intriguing findings emerged from an interaction test involving prior platinum exposure. Among patients who had previously received platinum chemotherapy, the hazard ratio for the triple-agent regimen versus monotherapy was 0.19, a dramatic reduction in the risk of progression or death, whereas among platinum-naive patients the hazard ratio was 1.11, showing essentially no difference. The interaction P-value of 0.039 suggests that platinum-pretreated patients may represent a subgroup particularly likely to benefit from the triplet, possibly because platinum sensitivity reflects underlying DNA damage repair deficiencies that also influence antibody-drug conjugate efficacy. The authors caution that this observation is exploratory and requires prospective validation, but it provides a concrete hypothesis for patient selection in future trials.

Safety data were reassuring. With prophylactic measures applied across the entire cohort, grade 3 or higher treatment-related adverse events occurred in 20.0 percent of monotherapy patients, 15.4 percent of the dual-combination group, and 14.3 percent of the triple-agent group, a difference that was not statistically significant. The most common severe toxicities were leukopenia and neutropenia across all groups. No treatment-related deaths were recorded, and no grade 3 or higher febrile neutropenia, hyperbilirubinemia, rash, or oral ulceration was reported. The starting dose of the antibody-drug conjugate was individualized according to performance status, with patients scoring 2 on the Eastern Cooperative Oncology Group scale receiving reduced starting doses below 80 percent of the standard level. Notably, an antibody-drug conjugate starting dose of at least 80 percent was associated with improved progression-free survival, underscoring the importance of maintaining dose intensity where tolerable.

Beyond the clinical outcomes, the research team developed an exploratory genomic scoring system aimed at identifying which patients are most likely to respond to the triple-agent strategy. The system incorporates mutations in 17 genes connected to Trop-2 antibody-drug conjugate sensitivity, homologous recombination repair, and angiogenesis pathways. Genes promoting therapeutic response, such as ATR, which may sensitize tumors to topoisomerase I inhibition and correlate with higher mutational burden and immunotherapy benefit, received positive weighted scores, while resistance-associated genes received negative scores. Patients whose total score exceeded zero were classified as likely to benefit from the triplet, and Fisher’s exact testing showed the classification was statistically significant. Genes such as VEGFRA and VEGFRB, tied to angiogenesis signaling, may indicate sensitivity to the anti-angiogenic component. The authors emphasize that the model’s principal value at this stage is hypothesis generation rather than clinical deployment.

The study also confirmed several prognostic patterns familiar from earlier research. Patients who initiated antibody-drug conjugate therapy in the second or third line had significantly longer progression-free survival than those treated later, at 5.8 versus 3.0 months. The presence of liver metastases, brain metastases, or visceral disease more broadly each independently predicted shorter progression-free survival after multivariable adjustment, with hazard ratios of 2.38, 2.51, and elevated risk for visceral involvement overall. These findings reinforce that disease biology and metastatic pattern remain dominant determinants of outcome even in the era of antibody-drug conjugates, and they highlight the need for improved risk stratification in biologically aggressive disease.

The investigators are transparent about the limitations inherent in a retrospective, single-center, non-randomized design. Selection bias and residual confounding cannot be excluded, baseline characteristics such as treatment line and PD-L1 status differed descriptively across groups, and the small size of the combination cohorts, 13 and 14 patients respectively, limits statistical power. Sensitivity analyses restricted to second- or third-line patients yielded directionally consistent but non-significant results, likely reflecting reduced sample size. To address these constraints, the team has launched a prospective randomized controlled trial, registered as NCT06851299, designed to rigorously test the efficacy and safety of Trop-2 antibody-drug conjugate-based combination regimens and to validate the genomic risk score. If those results confirm the signals described here, a triplet regimen combining a Trop-2 antibody-drug conjugate, PD-1 blockade, and anti-angiogenic therapy could reshape the treatment algorithm for one of breast cancer’s most lethal forms, extending meaningful survival to patients who currently have few good options.

Subject of Research: Trop-2-directed antibody-drug conjugate monotherapy and combination therapy for pretreated metastatic triple-negative breast cancer

Article Title: Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study

Article References: Liu, J., Ding, L., Wang, J., Chen, T., Long, T., Li, Q., Chai, J., Yao, H., Wang, Y., & Zhao, J. (2026). Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast Cancer Research and Treatment, 219(2), Article 10. https://doi.org/10.1007/s10549-026-08070-9

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08070-9

Keywords: Trop-2 antibody-drug conjugates, metastatic triple-negative breast cancer, sacituzumab govitecan, PD-1 inhibitors, anti-angiogenic therapy, triple-agent combination therapy, pembrolizumab, apatinib, progression-free survival, biomarker-guided therapy, real-world study, immune checkpoint inhibitors